Výsledky vyhľadávania - "Weissgerber, Georges"

Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration Autor Tadayoni, Ramin, Sararols, Laura, Weissgerber, Georges, Verma, Rohini, Clemens, Andreas, Holz, Frank G

“…Despite the success of anti-vascular endothelial growth factors (anti-VEGFs), currently, there is a need for highly effective compounds that can alleviate the…”
Zistit podrobnosti o prístupe

Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis Autor Schmidt-Erfurth, Ursula, Mulyukov, Zufar, Gerendas, Bianca S, Reiter, Gregor S, Lorand, Daniel, Weissgerber, Georges, Bogunović, Hrvoje

“…To assess the therapeutic response to brolucizumab and aflibercept by deep learning/OCT-based analysis of macular fluid volumes in neovascular age-related…”
Získať plný text

Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine (UK‐453,061), in healthy adult subjects Autor Langdon, Grant, Davis, John, Layton, Gary, Chong, Chew‐Lan, Weissgerber, Georges, Vourvahis, Manoli

“…WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Lersivirine (UK‐453,061) is predominantly cleared by glucuronidation (UGT2B7) and oxidation via cytochrome P450…”
Získať plný text

The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: target suppression using a biomarker Autor Lee, Lucy, Niu, Huifeng, Rueger, Ruediger, Igawa, Yuriko, Deutsch, Jonathan, Ishii, Nobuya, Mu, Song, Sakamoto, Yuuichiro, Busse-Reid, Rachel, Gimmi, Claude, Goelzer, Petra, De Schepper, Stefanie, Yoshimura, Yashushi, Barrett, Joanne, Ishikawa, Yuji, Weissgerber, Georges, Peck, Richard

“…CH4987655 (RO4987655) is an orally active and highly selective small-molecule MEK inhibitor. It potently inhibits mitogen-activated protein kinase signaling…”
Zistit podrobnosti o prístupe

Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects Autor Davis, John D., Hackman, Frances, Layton, Gary, Higgins, Tracy, Sudworth, David, Weissgerber, Georges

“…AIMS To assess the effect of a single dose of maraviroc on the QTc interval in healthy subjects and to evaluate the QTc interval–concentration relationship…”
Získať plný text

Cognitive testing in early-phase clinical trials: Development of a rapid computerized test battery and application in a simulated Phase I study Autor Collie, Alex, Darekar, Amanda, Weissgerber, Georges, Toh, Melvin K., Snyder, Peter J., Maruff, Paul, Huggins, John P.

“…Inclusion of cognitive assessment in Phase I trials of novel pharmaceutical agents may help identify subtle yet meaningful CNS effects early in clinical…”
Získať plný text

HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration Autor Dugel, Pravin U, Singh, Rishi P, Koh, Adrian, Ogura, Yuichiro, Weissgerber, Georges, Gedif, Kinfemichael, Jaffe, Glenn J, Tadayoni, Ramin, Schmidt-Erfurth, Ursula, Holz, Frank G

“…To report the 96-week outcomes from HAWK and HARRIER. Phase 3, prospective, randomized, double-masked, multicenter studies comparing efficacy and safety of…”
Zistit podrobnosti o prístupe

Pharmacogenomic Analysis of Response to Topical Tumor Necrosis Factor α Antagonist Licaminlimab (OCS-02) in Dry Eye Disease [RETRACTED]

“…The purpose of this study was to evaluate the pharmacogenomics of response to topical ocular tumor necrosis factor α (TNFα) inhibitor licaminlimab in patients…”
Zistit podrobnosti o prístupe

Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study Autor Holz, Frank G, Dugel, Pravin U, Weissgerber, Georges, Hamilton, Robin, Silva, Rufino, Bandello, Francesco, Larsen, Michael, Weichselberger, Andreas, Wenzel, Andreas, Schmidt, Anne, Escher, Dominik, Sararols, Laura, Souied, Eric

“…To assess the safety and efficacy of different doses of RTH258 applied as single intravitreal administration compared with ranibizumab 0.5 mg in patients with…”
Zistit podrobnosti o prístupe

Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK Autor Ogura, Yuichiro, Jaffe, Glenn J, Cheung, Chui Ming Gemmy, Kokame, Gregg T, Iida, Tomohiro, Takahashi, Kanji, Lee, Won Ki, Chang, Andrew A, Monés, Jordi, D’Souza, Divya, Weissgerber, Georges, Gedif, Kinfemichael, Koh, Adrian

“…PurposeTo compare the efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy (PCV) over 96 weeks in the HAWK…”
Získať plný text

EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Post Hoc Analysis of the HAWK and HARRIER Studies Autor Dugel, Pravin U, Jhaveri, Chirag D, Chakravarthy, Usha, Wykoff, Charles C, Singh, Rishi P, Hamilton, Robin, Weissgerber, Georges, Mulyukov, Zufar, Holz, Frank G

“…To determine the association between central subfield thickness (CST) variability and visual outcomes in eyes with neovascular age-related macular degeneration…”
Zistit podrobnosti o prístupe

A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration Autor Poor, Stephen H., Weissgerber, Georges, Adams, Christopher M., Bhatt, Harit, Browning, David J., Chastain, James, Ciulla, Thomas A., Ferriere, Michael, Gedif, Kinfemichael, Glazer, Louis C., Joondeph, Brian C., Normand, Guillaume, Sheth, Veeral, Watters, Christie, Grosskreutz, Cynthia L.

“…To evaluate whether topical acrizanib (LHA510), a small-molecule vascular endothelial growth factor receptor inhibitor, could suppress the need for…”
Získať plný text

Topical Anti-TNF[alpha] Agent Licaminlimab Autor Shettle, Lee, Seaman, John W., III, McLaurin, Eugene, Weissgerber, Georges, Martel, Joseph

“…Purpose: To assess the efficacy, safety, and pharmacokinetics of new topical ocular anti-TNF[alpha] antibody fragment licaminlimab in the relief of persistent…”
Získať plný text

Topical Anti-TNF[alpha] Agent Licaminlimab Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease: A Randomized Phase II Study Autor Shettle, Lee, McLaurin, Eugene, Martel, Joseph, Seaman, John W., III, Weissgerber, Georges

“…Purpose: To assess the efficacy, safety, and pharmacokinetics of new topical ocular anti-TNF[alpha] antibody fragment licaminlimab in the relief of persistent…”
Získať plný text

Topical Anti-TNFα Agent Licaminlimab (OCS-02) Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease: A Randomized Phase II Study Autor Shettle, Lee, McLaurin, Eugene, Martel, Joseph, Seaman, John W, Weissgerber, Georges

“…Purpose: To assess the efficacy, safety, and pharmacokinetics of new topical ocular anti-TNFα antibody fragment licaminlimab in the relief of persistent ocular…”
Získať plný text

Use of Composite End Points in Early and Intermediate Age-Related Macular Degeneration Clinical Trials: State-of-the-Art and Future Directions Autor Terheyden, Jan Henrik, Schmitz-Valckenberg, Steffen, Crabb, David P., Dunbar, Hannah, Luhmann, Ulrich F.O., Behning, Charlotte, Schmid, Matthias, Silva, Rufino, Cunha-Vaz, José, Tufail, Adnan, Weissgerber, Georges, Leal, Sergio, Holz, Frank G., Finger, Robert P.

“…The slow progression of early age-related macular degeneration (AMD) stages to advanced AMD requires the use of surrogate end points in clinical trials. The…”
Získať plný text

Topical Ocular Anti-TNFα Agent Licaminlimab in the Treatment of Acute Anterior Uveitis: A Randomized Phase II Pilot Study Autor Pasquali, Theodore A., Toyos, Melissa M., Abrams, David B., Scales, David K., Seaman, John W., Weissgerber, Georges

“…Licaminlimab is a new anti-TNFα antibody fragment for topical ocular application. This phase II study assessed the tolerability, treatment effect, and…”
Získať plný text

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of RO5068760, an MEK Inhibitor, in Healthy Volunteers: Assessment of Target Suppression Autor Lee, Lucy, Niu, Huifeng, Goelzer, Petra, Rueger, Ruediger, Deutsch, Jonathan, Busse-Reid, Rachel, DeSchepper, Stefanie, Blotner, Steve, Barrett, Joanne, Weissgerber, Georges, Peck, Richard

“…RO5068760, a substituted hydantoin, represents a new class of potent, highly selective, non‐adenosine triphosphate (ATP)–competitive MEK1/2 inhibitors. The…”
Získať plný text

Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects: A Review of the Clinical Pharmacology of Maraviroc Autor DAVIS, John D, HACKMAN, Frances, LAYTON, Gary, HIGGINS, Tracy, SUDWORTH, David, WEISSGERBER, Georges

Získať plný text

Activation of protein kinase C subtypes α, γ, δ, ϵ, ζ, and η by tumor-promoting and nontumor-promoting agents Autor Geiges, Detlef, Meyer, Thomas, Marte, Barbara, Vanek, Mirka, Weissgerber, Georges, Stabel, Silvia, Pfeilschifter, Josef, Fabbro, Doriano, Huwiler, Andrea

“…Protein kinase C (PKC) subtypes α, γ, δ, ϵ, ζ, and η have been expressed using the baculovirus expression system. The partially purified PKC subtypes have been…”
Získať plný text